Back to Search
Start Over
Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer
- Source :
- Cancer Prev Res (Phila), Cancer prevention research (Philadelphia, Pa.), vol 14, iss 7
- Publication Year :
- 2020
-
Abstract
- Early detection of pancreatic ductal adenocarcinoma (PDAC) is key to improving patient outcomes; however, PDAC is usually diagnosed late. Therefore, blood-based minimally invasive biomarker assays for limited volume clinical samples are urgently needed. A novel miRNA profiling platform (Abcam Fireplex-Oncology Panel) was used to investigate the feasibility of developing early detection miRNA biomarkers with 20 μL plasma from a training set (58 stage II PDAC cases and 30 controls) and two validation sets (34 stage II PDAC cases and 25 controls; 44 stage II PDAC cases and 18 controls). miR-34a-5p [AUC = 0.77; 95% confidence interval (CI), 0.66–0.87], miR-130a-3p (AUC = 0.74; 95% CI, 0.63–0.84), and miR-222-3p (AUC = 0.70; 95% CI, 0.58–0.81) were identified as significantly differentially abundant in plasma from stage II PDAC versus controls. Although none of the miRNAs individually outperformed the currently used serologic biomarker for PDAC, carbohydrate antigen 19-9 (CA19-9), combining the miRNAs with CA 19-9 improved AUCs from 0.89 (95% CI, 0.81–0.95) for CA 19-9 alone to 0.92 (95% CI, 0.86–0.97), 0.94 (95% CI, 0.89–0.98), and 0.92 (95% CI, 0.87–0.97), respectively. Gene set enrichment analyses of transcripts correlated with high and low expression of the three miRNAs in The Cancer Genome Atlas PDAC sample set. These miRNA biomarkers, assayed in limited volume plasma together with CA19-9, discriminate stage II PDAC from controls with good sensitivity and specificity. Unbiased profiling of larger cohorts should help develop an informative early detection biomarker assay for diagnostic settings. Prevention Relevance: Development of minimally invasive biomarker assays for detection of premalignant disease and early-stage pancreatic cancer is key to improving patient survival. This study describes a limited volume plasma miRNA biomarker assay that can detect early-stage resectable pancreatic cancer in clinical samples necessary for effective prevention and clinical intervention.
- Subjects :
- 0301 basic medicine
Oncology
Male
Cancer Research
Datasets as Topic
Disease
Serology
0302 clinical medicine
80 and over
Medicine
Stage (cooking)
Early Detection of Cancer
Cancer
Aged, 80 and over
screening and diagnosis
Blood Specimen Collection
Middle Aged
Detection
Pancreatic Ductal
030220 oncology & carcinogenesis
Biomarker (medicine)
Female
Biotechnology
Carcinoma, Pancreatic Ductal
Adult
medicine.medical_specialty
CA-19-9 Antigen
Clinical Sciences
Oncology and Carcinogenesis
Article
Pancreatic Cancer
03 medical and health sciences
Young Adult
Rare Diseases
Text mining
Clinical Research
Internal medicine
Pancreatic cancer
microRNA
Genetics
Humans
Oncology & Carcinogenesis
Pancreas
Aged
Neoplasm Staging
business.industry
Prevention
Carcinoma
medicine.disease
Confidence interval
4.1 Discovery and preclinical testing of markers and technologies
Pancreatic Neoplasms
MicroRNAs
Good Health and Well Being
030104 developmental biology
ROC Curve
Case-Control Studies
Feasibility Studies
Digestive Diseases
business
Subjects
Details
- ISSN :
- 19406215
- Volume :
- 14
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- Cancer prevention research (Philadelphia, Pa.)
- Accession number :
- edsair.doi.dedup.....1580e24a9fd20eba6aa1440cbcda1e20